201 related articles for article (PubMed ID: 26886301)
21. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.
Bhat R; Tummalapalli SR; Rotella DP
J Med Chem; 2014 Nov; 57(21):8718-28. PubMed ID: 25141341
[TBL] [Abstract][Full Text] [Related]
22. Recent update on discovery and development of Hsp90 inhibitors as senolytic agents.
Dutta Gupta S; Pan CH
Int J Biol Macromol; 2020 Oct; 161():1086-1098. PubMed ID: 32561284
[TBL] [Abstract][Full Text] [Related]
23. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
24. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
25. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting HSP90 to treat cancer: a strategy in evolution.
Whitesell L; Santagata S; Lin NU
Curr Mol Med; 2012 Nov; 12(9):1108-24. PubMed ID: 22804235
[TBL] [Abstract][Full Text] [Related]
27. Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy.
Xie X; Zhang N; Li X; Huang H; Peng C; Huang W; Foster LJ; He G; Han B
Bioorg Chem; 2023 Oct; 139():106721. PubMed ID: 37467620
[TBL] [Abstract][Full Text] [Related]
28. HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy.
Jafari A; Rezaei-Tavirani M; Farhadihosseinabadi B; Taranejoo S; Zali H
Cancer Invest; 2020 May; 38(5):310-328. PubMed ID: 32274949
[TBL] [Abstract][Full Text] [Related]
29. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
30. From the bench to the bed side: PI3K pathway inhibitors in clinical development.
Maira SM; Finan P; Garcia-Echeverria C
Curr Top Microbiol Immunol; 2010; 347():209-39. PubMed ID: 20582534
[TBL] [Abstract][Full Text] [Related]
31. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
32. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
33. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
Kabakov AE; Kudriavtsev VA; Makarova IuM
Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
[TBL] [Abstract][Full Text] [Related]
34. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
Baselga J
Ann Oncol; 2008 Sep; 19 Suppl 7():vii281-8. PubMed ID: 18790967
[No Abstract] [Full Text] [Related]
35. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress.
Liu Y; Li C; Liu H; Tan S
Arch Pharm Res; 2024 May; 47(5):442-464. PubMed ID: 38632167
[TBL] [Abstract][Full Text] [Related]
37. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
Jhaveri K; Ochiana SO; Dunphy MP; Gerecitano JF; Corben AD; Peter RI; Janjigian YY; Gomes-DaGama EM; Koren J; Modi S; Chiosis G
Expert Opin Investig Drugs; 2014 May; 23(5):611-28. PubMed ID: 24669860
[TBL] [Abstract][Full Text] [Related]
38. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
Bussenius J; Blazey CM; Aay N; Anand NK; Arcalas A; Baik T; Bowles OJ; Buhr CA; Costanzo S; Curtis JK; DeFina SC; Dubenko L; Heuer TS; Huang P; Jaeger C; Joshi A; Kennedy AR; Kim AI; Lara K; Lee J; Li J; Lougheed JC; Ma S; Malek S; Manalo JC; Martini JF; McGrath G; Nicoll M; Nuss JM; Pack M; Peto CJ; Tsang TH; Wang L; Womble SW; Yakes M; Zhang W; Rice KD
Bioorg Med Chem Lett; 2012 Sep; 22(17):5396-404. PubMed ID: 22877636
[TBL] [Abstract][Full Text] [Related]
39. Targeting autophagy to overcome drug resistance in cancer therapy.
Kumar A; Singh UK; Chaudhary A
Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
[TBL] [Abstract][Full Text] [Related]
40. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]